Surgery Partners, Inc. (SGRY)
Valor JustoFundamental
53
Preço
$13.64
Capitalização de Mercado
$1.82B
Parte 1 · Quanto vale a empresa
Visão Geral
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$3.37B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$-89M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$196M
Capital Próprio Total
$1.71B
Passivo Total
$4.99B
Rácio de Liquidez
1.95
Cobertura de Juros
-
Dívida/EBITDA
7.18
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$17.03
Preço Atual
$13.64
Margem de Segurança
+19.9%
Intervalo de Valor Justo
$14.57 - $19.50
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-4.5%
Rácio P/B
1.09
P/FCF
9.68
Margem Bruta
-
ROIC
4.1%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
4.1%
WACC
4.9%
ROIC − WACC
-0.8 pp
O ROIC está próximo do custo do capital — a empresa cobre apenas o custo do capital.
Critérios de Análise Fundamental
Aprovado (12)
- P/FCF 9.68
- P/B Ratio 1.09
- Debt/Equity ratio
- Operating Margin 11.4%
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 12.2%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 14.8%
- Share Dilution 1.0%
- Net Margin Trend -2.6% vs -5.6%
- Piotroski F-Score 5/9
Reprovado (9)
- EPS shows upward trend
- Price CAGR -0.85%
- ROIC 4.1%
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Fairly valued)
- ROE -5.3%
Indisponível (6)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
Número de ações estável
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. J. Eric Evans | CEO & Director | 48 |
| Mr. David T. Doherty CPA | Executive VP & CFO | 53 |
| Ms. Jennifer B. Baldock J.D. | Executive VP and Chief Administrative & Development Officer | 54 |
| Ms. Marissa A. Brittenham | Executive VP & Chief Strategy Officer | 40 |
| Mr. W. Trent Webb | Division President South | 45 |
| Mr. Justin R. Oppenheimer | Executive VP & COO | 40 |
| Mr. Jon Fredrickson | Senior VP & Chief Information Officer | - |
| Ms. Roxanne Womack | Senior VP & Chief Compliance Officer | - |
| Mr. Spencer Clark | General Counsel & Senior VP | - |
| Ms. Danielle Burkhalter | Executive VP & Chief Human Resources Officer | 40 |
Risco de Auditoria
9
Risco do Conselho
6
Risco de Remuneração
4
Risco dos Direitos dos Acionistas
8
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-03-02
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-10
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-09-17
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for SGRY, sourced from Markets Gazette.
- 3/3/2026NEGATIVESurgery Partners Stock Hits 52-Week Low - Here's Why
Markets Gazette reports a significant downturn for Surgery Partners, whose shares (SGRY) hit a new 52-week low in premarket trading. The decline was triggered by the release of financial results that fell short of analysts' expectations. Furthermore, the company provided a cautious outlook for 2026, fueling investor concerns regarding future growth and profitability. This development suggests downward pressure on the stock, with the market reacting negatively to both current performance and near-term prospects. Investors should closely monitor the evolution of the company's strategy and upcoming reports to assess any signs of recovery.
- 2/23/2026NEGATIVESurgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million
Shares of Surgery Partners, a healthcare firm operating a national network of surgical centers, plummeted by a staggering 39%. The sharp decline was triggered by news that a major investment fund slashed its stake in the company, selling off shares worth $19 million. Such a substantial divestment by an institutional investor is a significant red flag for the market, often interpreted as a loss of confidence in the company's future prospects or valuation. This large-scale sell-off has created immense downward pressure on the stock, reflecting widespread investor concern. Traders will now be closely watching for any follow-up from the company or further signs of institutional selling to gauge the underlying reasons for the fund's exit.
via Markets Gazette